LFB Biopharmaceuticals Limited Takes Over Promotion Of LFB Group’s Biopharmaceuticals In The United Kingdom

LONDON--(BUSINESS WIRE)--LFB BIOPHARMACEUTICALS, a wholly owned subsidiary of LFB S.A, takes over the promotion of LFB’s biopharmaceutical products for serious and rare diseases to healthcare professionals, in the United Kingdom. Following the introduction of WILLFACT®, LFB’s von Willebrand factor, for the treatment of von Willebrand disease, further launches will follow for immunoglobulin, fibrinogen, and recombinant proteins in the fields of Haemostasis, Immunology and Intensive care, these products currently being under advanced clinical development.

“LFB BIOPHARMACEUTICALS is our flagship in the United Kingdom, one of the most important markets in Europe”

“LFB BIOPHARMACEUTICALS is our flagship in the United Kingdom, one of the most important markets in Europe” says Philippe Gredy, LFB’s Global Marketing & Sales Vice-President. “Run by Jane Shepard, our Business Director, we are confident LFB BIOPHARMACEUTICALS will successfully launch several high standard LFB medicinal products in United Kingdom hospitals, in the interest of patients suffering from serious, rare, chronic conditions.”

LFB BIOPHARMACEUTICALS Ltd is LFB’s second active promotional subsidiary in Europe, following the successful establishment of LFB GmbH in Germany. In France, LFB is a major biopharmaceutical player, leading the French plasma derivatives market, and a top supplier of hospital medicines in the country.

The LFB group currently markets its 23 medicines in more than 40 countries and 28% of its turnover is generated by international business. Created in 1994, the LFB was founded on a fundamental commitment: ensuring patients’ safety. It is today a rapidly growing biopharmaceutical group, specialized in biological medicinal products, focusing on innovation both in therapeutic and technological fields.

About LFB
The LFB group (www.lfb.fr) is a biopharmaceutical company that develops, manufactures, and markets medicinal products for the treatment of serious and often rare diseases in the fields of Immunology, Haemostasis, Perinatal, and Intensive Care. The LFB group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide, and is also among the leading European companies for the development of new-generation medicinal products or treatments based on biotechnologies.
The LFB group is pursuing a growth strategy that seeks to extend its international activities and develop innovative therapies. Today, the LFB group currently markets its products in more than 40 countries around the world with a global turnover of € 501,9 million in 2014.